The GLOBAL SYMPLICITY Registry is the largest study, with the longest followup, of real-world patients (real world data) presenting high blood pressure, treated with renal denervation. Time in Target Range (TTR), estimates the time a patient needs to control their blood pressure, and is an independent predictor of cardiovascular events. The aim of this registry,...
Most hypertensive patients do not reach target blood pressure level ranges despite optimal medical treatment. Regardless anti-hypertensive medication, patients undergoing radiofrequency renal denervation have seen significant improved control of blood pressure, with relevant clinical impact. One of the outcomes we look at in chronic diseases such as hypertension and diabetes is time in target range...
Though the different percutaneous valves have been designed and authorized for aortic stenosis with tricuspid valve, they have often been used to treat aortic regurgitation as an off-label indication. The Jenavalve Trilogy valve has recently received the CE Mark for aortic regurgitation and aortic stenosis. This study included 45 patients with severe AR. Primary end...
TAVR is a valid alternative to treat failed surgical bioprosthetic valves, but one of its biggest challenges is patients with a small annulus. When using self-expanding valves, supra-annular implantation is recommended. However, at present, we only have retrospective, observational studies, not large enough. The LYTEN Trial is a randomized study in patients presenting failed bioprosthetic...
This study presented at EuroPCR 2022 analyzed the PARTNER study pool and included 1974 patients with a complete echocardiogram. Surgical risk was 17.3% extreme/inoperable, 54.3% intermediate and 28.4% low. 60% received transcatheter aortic valve replacement (TAVR) and the rest surgical aortic valve replacement (SAVR). 6.1% of patients were in stage 0 (no damage), 14.5% were...
It is still unclear whether surgical aortic valve replacement (SAVR) is beneficial in asymptomatic patients with severe aortic stenosis (AS) and conserved left ventricular function (C1 indication according to AHA guidelines). The European American guidelines only recommend intervention in asymptomatic patient when there is ventricular compromise (ejection fraction <50%, class I indication) or with a...
The recommended treatment for ST elevation acute myocardial infarction (STEMI) is early PCI, typically stenting. However, stent implantation always involves the risk of intravascular complications, such as stent thrombosis or restenosis. Sometimes stable flow is restored to the target vessel after initial PCI and we can omit stenting when there is no angiographically significant residual...
Difficult to treat, tricuspid valve failure poses great medical challenge. In addition, the mortality rate of surgical treatment these days is not exactly low, involving high risk, which often takes this alternative off the table. Several percutaneous devices have been developed to treat this disease, the most popular being edge-to-edge devices. The TRICENTO has an...
Dual antiplatelet therapy (DAPT) after PCI with DES has shown noticeable reduction of thrombotic events, especially in acute coronary syndromes (ACS). However, this therapy encompasses increased bleeding, especially in elderly patients increasingly undergoing percutaneous intervention. Even though most bleeding events might not be fatal (many of them are mostly digestive) they do involve higher hospitalization...
Compared with patients with chronic coronary syndromes, patients with acute coronary syndromes (ACS) are more likely to suffer from long term major adverse cardiac events (MACE). To prevent this, both the American and the European guidelines recommend prolonging dual antiplatelet therapy (DAPT) in this population for at least 12 months. However, in patients with certain clinical...